Assessment of synovitis to predict bone erosions in rheumatoid arthritis

Therapeutic Advances in Musculoskeletal Disease

Volumn 4, Issue 4, 2012, Pages 235-244

  Bugatti, Serena ^a   Manzo, Antonio ^a   Caporali, Roberto ^a   Montecucco, Carlomaurizio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

biomarker; bone erosion; rheumatoid arthritis; synovitis

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD68 ANTIGEN; CXCL13 CHEMOKINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GRANZYME B; IMMUNOGLOBULIN M; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 22; INTERLEUKIN 6; LEUKOCYTE ANTIGEN; METHOTREXATE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

AGE DISTRIBUTION; ARTICLE; BONE EROSION; BONE MARROW EDEMA; CLINICAL ASSESSMENT; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; HISTOPATHOLOGY; HUMAN; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOGENESIS; PHYSICAL EXAMINATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; STRATEGIC PLANNING; SYNOVITIS; SYNOVIUM; UPREGULATION;

EID: 84868644374     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X12453092     Document Type: Article

References (86)

1. Aletaha D. Alasti F. Smolen J. (2011) Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression. Ann Rheum Dis 70: 1975–1980.
2. Aletaha D. Funovits J. Keystone E. Smolen J. (2007) Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 56: 3226–3235.
3. Aletaha D. Smolen J. (2011) Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum 63: 3702–3711.
4. Baeten D. Kruithof E. de Rycke L. Boots A. Mielants H. Veys E. et al. (2005) Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 7: R359–R369.
5. Ballara S. Taylor P. Reusch P. Marmé D. Feldmann M. Maini R. et al. (2001) Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 44: 2055–2064.
6. Boers M. Kostense P. Verhoeven A. van der Linden S. for the COBRA Trial Group (2001) Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis. Arthritis Rheum 44: 2242–2246.
7. Bøyesen P. Haavardsholm E. Ostergaard M. van der Heijde D. Sesseng S. Kvien T. (2011) MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression. Ann Rheum Dis 70: 428–433.
8. Brown A. Conaghan P. Karim Z. Quinn M. Ikeda K. Peterfy C. et al. (2008) An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 58: 2958–2967.
9. Brown A. Quinn M. Karim Z. Conaghan P. Peterfy C. Hensor E. et al. (2006) Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 54: 3761–3773.
10. Bugatti S. Manzo A. Benaglio F. Klersy C. Vitolo B. Todoerti M. et al. (2012) Serum levels of CXCL 13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs. Arthritis Res Ther 14: R34.
11. Bugatti S. Manzo A. Bombardieri M. Vitolo B. Humby F. Kelly S. et al. (2011 a) Synovial tissue heterogeneity and peripheral blood biomarkers. Curr Rheumatol Rep 13: 440–448.
12. Bugatti S. Manzo A. Vitolo B. Fusetti C. Humby F. Caporali R. et al. (2011 b) B cell distribution and activation-induced cytidine deaminase expression in rheumatoid synovitis: clinical and bio-molecular correlates. Ann Rheum Dis 70: A55.
13. Cañete J. Celis R. Moll C. Izquierdo E. Marsal S. Sanmartí R. et al. (2009) Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 68: 751–756.
14. Cantaert T. Kolln J. Timmer T. van der Pouw Kraan T. Vandooren B. Thurlings R. et al. (2008) B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis. J Immunol 181: 785–794.
15. Combe B. Dougados M. Goupille P. Cantagrel A. Eliaou J. Sibilia J. et al. (2001) Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum 44: 1736–1743.
16. Courvoisier N. Dougados M. Cantagrel A. Goupille P. Meyer O. Sibilia J. et al. (2008) Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther 10:R106.
17. de Hair M. Harty L. Gerlag D. Pitzalis C. Veale D. Tak P. (2011) Synovial tissue analysis for the discovery of diagnostic and prognostic biomarkers in patients with early arthritis. J Rheumatol 38: 2068–2072.
18. Drouin J. Haraoui B. for the 3e Initiative Group (2010) Predictors of clinical response and radiographic progression in patients with rheumatoid arthritis treated with methotrexate monotherapy. J Rheumatol 37: 1405–1410.
19. Drossaers-Bakker K. de Buck M. van Zeben D. Zwinderman A. Breedveld F. Hazes J. (1999) Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 42: 1854–1860.
20. Ellegaard K. Torp-Pedersen S. Henriksen M. Lund H. Danneskiold-Samsøe B. Bliddal H. (2009) Influence of recent exercise and skin temperature on ultrasound Doppler measurements in patients with rheumatoid arthritis - an intervention study. Rheumatology 48: 1520–1523.
21. Forslind K. Ahlmén M. Eberhardt K. Hafström I. Svensson B. for the BARFOT Study Group (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63: 1090–1095.
22. Fukae J. Kon Y. Henmi M. Sakamoto F. Narita A. Shimizu M. et al. (2010) Change of synovial vascularity in a single finger joint assessed by power Doppler sonography correlated with radiographic change in rheumatoid arthritis: comparative study of a novel quantitative score with a semiquantitative score. Arthritis Care Res 62: 657–663.
23. Gabay C. Kushner I. (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448–454.
24. Goldbach-Mansky R. Suson S. Wesley R. Hack C. El-Gabalawy H. Tak P. (2005) Raised granzyme B levels are associated with erosions in patients with early rheumatoid factor positive rheumatoid arthritis. Ann Rheum Dis 64: 715–721.
25. Haringman J. Gerlag D. Zwinderman A. Smeets T. Kraan M. Baeten D. et al. (2005) Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64: 834–838.
26. Hetland M. Ejbjerg B. Hørslev-Petersen K. Jacobsen S. Vestergaard A. Jurik A. et al. (2009) MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 68: 384–390.
27. Hetland M. Stengaard-Pedersen K. Junker P. Østergaard M. Ejbjerg B. Jacobsen S. et al. (2010) Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 69: 1789–1795.
28. Hitchon C. El-Gabalawy H. (2011) The synovium in rheumatoid arthritis. Open Rheumatol J 5: 107–114.
29. Humby F. Bombardieri M. Manzo A. Kelly S. Blades M. Kirkham B. et al. (2009) Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med 6: e1.
30. Jimenez-Boj E. Nöbauer-Huhmann I. Hanslik-Schnabel B. Dorotka R. Wanivenhaus A. Kainberger F. et al. (2007) Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum 56: 1118–1124.
31. Kaarela K. (1985) Prognostic factors and diagnostic criteria in early rheumatoid arthritis. Scand J Rheumatol Suppl 57: 1–54.
32. Karsdal M. Woodworth T. Henriksen K. Maksymowych W. Genant H. Vergnaud P. et al. (2011) Biochemical markers of ongoing joint damage in rheumatoid arthritis–current and future applications, limitations and opportunities. Arthritis Res Ther 13: 215.
33. Klarenbeek N. Güler-Yüksel M. van der Heijde D. Hulsmans H. Kerstens P. Molenaar T. et al. (2010) Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab. Ann Rheum Dis 69: 2107–2113.
34. Klimiuk P. Sierakowski S. Latosiewicz R. Cylwik J. Cylwik B. Skowronski J. et al. (2003) Circulating tumour necrosis factor alpha and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis. Ann Rheum Dis 62: 472–475.
35. Kraan M. Haringman J. Weedon H. Barg E. Smith M. Ahern M. et al. (2004) T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 63:483–488.
36. Kraan M. Versendaal H. Jonker M. Bresnihan B. Post W. t Hart B. et al. (1998) Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 41: 1481–2148
37. Kuuliala A. Eberhardt K. Takala A. Kautiainen H. Repo H. Leirisalo-Repo M. (2002) Circulating soluble E-selectin in early rheumatoid arthritis: a prospective five year study. Ann Rheum Dis 61: 242–246.
38. Leipe J. Schramm M. Grunke M. Baeuerle M. Dechant C. Nigg A. et al. (2011) Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis. Ann Rheum Dis 70: 1453–1457.
39. Liao K. Weinblatt M. Cui J. Iannaccone C. Chibnik L. Lu B. et al. (2011) Clinical predictors of erosion-free status in rheumatoid arthritis: a prospective cohort study. Rheumatology 50: 1473–1479.
40. Lillegraven S. van der Heijde D. Uhlig T. Kvien T. Haavardsholm E. (2012) What is the clinical relevance of erosions and joint space narrowing in RA? Nat Rev Rheumatol, DOI: 10.1038/nrrheum.2011.20210.1038/nrrheum.2011.202.
41. Lindqvist E. Eberhardt K. Bendtzen K. Heinegård D. Saxne T. (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64: 196–201.
42. Lindqvist E. Jonsson K. Saxne T. Eberhardt K. (2003) Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 62: 611–616.
43. Loetscher P. Moser B. (2002). Homing chemokines in rheumatoid arthritis. Arthritis Res 4: 233–236.
44. Lukas C. van der Heijde D. Fatenajad S. Landewé R. (2010) Repair of erosions occurs almost exclusively in damaged joints without swelling. Ann Rheum Dis 69: 851–855.
45. Machold K. Stamm T. Nell V. Pflugbeil S. Aletaha D. Steiner G. et al. (2007) Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology 46: 342–349.
46. Manzo A. Bombardieri M. Humby F. Pitzalis C. (2010) Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: from inflammation to autoimmunity and tissue damage/remodeling. Immunol Rev 233: 267–285.
47. Manzo A. Vitolo B. Humby F. Caporali R. Jarrossay D. Dell'accio F. et al. (2008) Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL 13 in the inflammatory environment of the rheumatoid joint. Arthritis Rheum 58: 3377–3387.
48. Markatseli T. Papagoras C. Drosos A. (2010) Prognostic factors for erosive rheumatoid arthritis. Clin Exp Rheumatol 28: 114–123.
49. McQueen F. Benton N. Perry D. Crabbe J. Robinson E. Yeoman S. et al. (2003) Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 48: 1814–1827.
50. McQueen F. Gao A. Ostergaard M. King A. Shalley G. Robinson E. et al. (2007) High-grade MRI bone oedema is common within the surgical field in rheumatoid arthritis patients undergoing joint replacement and is associated with osteitis in subchondral bone. Ann Rheum Dis 66: 1581–1587.
51. McQueen F. Stewart N. Crabbe J. Robinson E. Yeoman S. Tan P. et al. (1999) Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Ann Rheum Dis 58: 156–163.
52. Meeuwisse C. van der Linden M. Rullmann T. Allaart C. Nelissen R. Huizinga T. et al. (2011) Identification of CXCL 13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. Arthritis Rheum 63: 1265–1273.
53. Meyer O. Labarre C. Dougados M. Goupille P. Cantagrel A. Dubois A. et al. (2003) Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62: 120–126.
54. Mo Y. Dai L. Zheng D. Zhu L. Wei X. Pessler F. et al. (2011) Synovial infiltration with CD79a-positive B cells, but not other B cell lineage markers, correlates with joint destruction in rheumatoid arthritis. J Rheumatol 38: 2301–2308.
55. Mulherin D. Fitzgerald O. Bresnihan B. (1996) Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 39: 115–124.
56. Naredo E. Bonilla G. Gamero F. Uson J. Carmona L. Laffon A. (2005) Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. Ann Rheum Dis 64: 375–381.
57. Naredo E. Collado P. Cruz A. Palop M. Cabero F. Richi P. et al. (2007) Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression. Arthritis Rheum 57: 116–124.
58. Nell V. Machold K. Eberl G. Stamm T. Uffmann M. Smolen J. (2004) Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 43: 906–914.
59. Østergaard M. Peterfy C. Conaghan P. McQueen F. Bird P. Ejbjerg B. et al. (2003) OMERACT Rheumatoid Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 30: 1385–1386.
60. Reynolds P. Heron C. Pilcher J. Kiely P. (2009) Prediction of erosion progression using ultrasound in established rheumatoid arthritis: a 2-year follow-up study. Skeletal Radiol 38: 473–478.
61. Rezaei H. Saevarsdottir S. Forslind K. Albertsson K. Wallin H. Bratt J. et al. (2012) In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. Ann Rheum Dis 71: 186–191.
62. Rioja I. Hughes F. Sharp C. Warnock L. Montgomery D. Akil M. et al. (2008) Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum 58: 2257–2267.
63. Rooney T. Roux-Lombard P. Veale D. FitzGerald O. Dayer J. Bresnihan B. (2010) Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade. Ann Rheum Dis 69: 706–714.
64. Rosengren S. Wei N. Kalunian K. Kavanaugh A. Boyle D. (2011) CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology 50: 603–610.
65. Roux-Lombard P. Eberhardt K. Saxne T. Dayer J. Wollheim F. (2001) Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology 40: 544–551.
66. Schett G. (2007) Joint remodelling in inflammatory disease. Ann Rheum Dis 66(Suppl. 3): iii42–iii44.
67. Scirè C. Montecucco C. Codullo V. Epis O. Todoerti M. Caporali R. (2009) Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology 48: 1092–1097.
68. Scott D. Pugner K. Kaarela K. Doyle D. Woolf A. Holmes J. et al. (2000) The links between joint damage and disability in rheumatoid arthritis. Rheumatology 39: 122–132.
69. Smolen J. Han C. Bala M. Maini R. Kalden J. van der Heijde D. et al. (2005) Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52: 1020–1030.
70. Smolen J. van der Heijde D. St.Clair E. Emery P. Bathon J. Keystone E. et al. for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with highdose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54: 702–710.
71. Suter L. Fraenkel L. Braithwaite R. (2011) Role of magnetic resonance imaging in the diagnosis and prognosis of rheumatoid arthritis. Arthritis Care Res 63: 675–688.
72. Syversen S. Gaarder P. Goll G. Ødegård S. Haavardsholm E. Mowinckel P. et al. (2008) High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 67: 212–217.
73. Tak P. Smeets T. Daha M. Kluin P. Meijers K. Brand R. et al. (1997) Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 40: 217–225.
74. Takemura S. Braun A. Crowson C. Kurtin P. Cofield R. O'Fallon W. et al. (2001) Lymphoid neogenesis in rheumatoid synovitis. J Immunol 167: 1072–1080.
75. Taylor P. Steuer A. Gruber J. Cosgrove D. Blomley M. Marsters P. et al. (2004) Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 50: 1107–1116.
76. Terslev L. von der Recke P. Torp-Pedersen S. Koenig M. Bliddal H. (2008) Diagnostic sensitivity and specificity of Doppler ultrasound in rheumatoid arthritis. J Rheumatol 35: 49–53.
77. Thurlings R. Wijbrandts C. Mebius R. Cantaert T. Dinant H. van der Pouw-Kraan T. et al. (2008) Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. Arthritis Rheum 58: 1582–1589.
78. van de Sande M. Gerlag D. Lodde B. van Baarsen L. Alivernini S. Codullo V. et al. (2011) Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Ann Rheum Dis 70: 423–427.
79. van der Helm-van Mil A. Verpoort K. Breedveld F. Toes R. Huizinga T. (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7: R949–R958.
80. van der Linden M. Boja R. Klarenbeek N. Huizinga T. van der Heijde D. van der Helm-van Mil A. (2010) Repair of joint erosions in rheumatoid arthritis: prevalence and patient characteristics in a large inception cohort. Ann Rheum Dis 69: 727–729.
81. van Leeuwen M. van der Heijde D. van Rijswijk M. Houtman P. van Riel P. van de Putte L. et al. (1994) Interrelationship of outcome measures and process variables in early rheumatoid arthritis: a comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 21: 425–429.
82. Vastesaeger N. Xu S. Aletaha D. St Clair E. Smolen J. (2009) A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology 48: 1114–1121.
83. Visser K. Goekoop-Ruiterman Y. de Vries-Bouwstra J. Ronday H. Seys P. Kerstens P. et al. (2010) A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis 69: 1333–1337.
84. Walsh N. Gravallese E. (2010) Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 233: 301–312.
85. Welsing P. van Gestel A. Swinkels H. Kiemeney L. van Riel P. (2001) The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 44: 2009–2017.
86. Zayat A. Conaghan P. Sharif M. Freeston J. Wenham C. Hensor E. et al. (2011) Do non-steroidal anti-inflammatory drugs have a significant effect on detection and grading of ultrasound-detected synovitis in patients with rheumatoid arthritis? Results from a randomised study. Ann Rheum Dis 70: 1746–1751.